Other key parameters mechanistically considered are the expression levels of the immune checkpoints (particularly PD-L1 on cancer cells, which is a known biomarker of anti-PD-1 efficacy), and inhibitory immune cells, such as T-regulatory cells present in the lymph nodes and the tumor microenvironment. Here, PDCD1 is linked to cancer.